Satellos Bioscience, a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate a Phase 2 clinical study in FSHD in the fourth quarter of 2026. Satellos also announced that the FSHD Canada Foundation has agreed to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD.
Satellos is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.